Who is the CEO of Sai Life Sciences Ltd?
- Answer Field
-
Kanumuri Ranga Raju is the CEO of Sai Life Sciences Ltd, leading the company with extensive experience in CRDMO and pharmaceutical services.
BAJAJ BROKING
Incorporated in January 1999, Sai Life Sciences Limited is a global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in small-molecule new chemical entities (NCE). With over two decades of experience, the company provides tailored services to global biotech and pharmaceutical companies, including 18 of the top 25 pharma firms worldwide.
The company operates across the CRDMO value chain, offering discovery, development, and manufacturing solutions. With an experienced scientific team and operations spanning the US, UK, Europe, and Japan, Sai Life Sciences is positioned as an integrated healthcare innovator. For more details, visit the Sai Life Sciences IPO page.
Details | Specifications |
IPO Date | December 11, 2024 - December 13, 2024 |
Issue Size | ₹3,042.62 crore |
Price Band | ₹522 - ₹549 per share |
Face Value | ₹1 per share |
Lot Size | 27 shares |
Fresh Issue | ₹950 crore |
Offer for Sale | ₹2,092.62 crore |
Listing At | BSE, NSE |
Purpose of the IPO
Event | Date |
IPO Opening Date | December 11, 2024 |
IPO Closing Date | December 13, 2024 |
Allotment Finalization | December 16, 2024 |
Refund Initiation | December 17, 2024 |
Credit of Shares | December 17, 2024 |
Listing Date | December 18, 2024 |
Price Band for the IPO
Minimum Lot Size and Application Details
Online Application Process
Key Financial Metrics
Recent Performance and Growth Prospects
Potential Risks of Investing in the IPO
Opportunities and Growth Potential
KPI | Value |
ROE | 11.79% |
ROCE | 15.96% |
RoNW | 8.13% |
P/BV | 10.18 |
PAT Margin | 5.65% |
Role | Details |
Registrar | Kfin Technologies Limited |
Lead Managers | Kotak Mahindra Capital, Jefferies India, Morgan Stanley India, IIFL Securities |
Details | Information |
Address | Plot No. DS-7, IKP Knowledge Park, Turkapally Village, Shameerpet Mandal, Malkajgiri District, Hyderabad-500078 |
Phone | +9140 6815 6000 |
investors@sailife.com | |
Website |
Sai Life Sciences IPO represents a structured approach for investors interested in the CRDMO and pharmaceutical research industries. With its growing financials and global client base, the company showcases its market potential.
Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your IPO allotment status for Sai Life Sciences IPO.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Gold Rate Today | 15 January 2025 | Gold Price in India
15 Jan, 2025 | 40 Min. read
Delhi Court Discharges JSW Steel in Corruption Case; HC Clears Monnet Takeover
15 Jan, 2025 | 2 Min. read
IRFC Emerges L1 Bidder to Finance ₹3,167 Crore for Banhardih Coal Block
15 Jan, 2025 | 2 Min. read
Cipla’s Tax Demand Reduced to ₹559.18 Crores After Revision
15 Jan, 2025 | 2 Min. read
Govt Plans 5-6% Hike in Highway Budget for FY26 After FY25 Slump
15 Jan, 2025 | 2 Min. read
Rikhav Securities IPO- Key Objective & Deep Analysis
15 Jan, 2025 | 5 Min. read
HCL Tech expands partnership with Microsoft to transform contact centres
14 Jan, 2025 | 2 Min. read
BEL secures new orders worth Rs 561 crore, boosting FY25 order book
14 Jan, 2025 | 2 Min. read
ITI Ltd secures Rs 64 crore contracts for Wi-Fi and CCTV systems
14 Jan, 2025 | 2 Min. read
JSW Energy secures LoI for 3.6 GW KSK Mahanadi power plant
14 Jan, 2025 | 2 Min. read
Biocon Biologics’ Johor Bahru Facility Receives FDA VAI Classification
13 Jan, 2025 | 2 Min. read
Interarch Secures ₹221 Crore Projects in Semiconductors & Energy Storage
13 Jan, 2025 | 2 Min. read
RBI Launches ULI: Transforming Loan Access
August 27, 2024 | 4 Min. read
Textile Sector in India
September 20, 2024 | 5 Min. read
List of IPOs with DRHPs Filed
November 30, 2023 | 3 Min. read
Aditya Birla Group
September 28, 2023 | 10 Min. read
Bajaj Housing Finance Ltd IPO: Things Smart Investors Need to Know
September 05, 2024 | 4 Min. read
Budget Stock Ideas 2024-2025 | Stocks to Buy Today
July 24, 2024 | 4 Min. read
IPO Eligibility Criteria : Full Details
March 15, 2024 | 6 Min. read
What Is the Lock-In Period in IPOs?
October 18, 2023 | 6 Min. read
Godfrey Phillips Announces 2:1 Bonus Shares
September 16, 2024 | 7 Min. read
Jindal Group- A Comprehensive Analysis
September 27, 2024 | 7 Min. read
Kanumuri Ranga Raju is the CEO of Sai Life Sciences Ltd, leading the company with extensive experience in CRDMO and pharmaceutical services.
The Sai Life Sciences IPO opens on December 11, 2024, and closes on December 13, 2024.
Sai Life Sciences specializes in CRDMO services, offering discovery, development, and manufacturing solutions to global pharma companies. Its integrated approach ensures scalability and sustainability.
The issue size of Sai Life Sciences IPO is ₹3,042.62 crore, comprising ₹950 crore from a fresh issue and ₹2,092.62 crore from an offer for sale.
‘Pre-apply’ enables investors to bid for the IPO before its official opening, ensuring early participation in the subscription process.
Once the UPI mandate is approved, your application will be confirmed. Updates can be tracked on your trading platform or the registrar’s website.
The minimum lot size for the Sai Life Sciences IPO is 27 shares, requiring a retail investment of ₹14,823.
The allotment for Sai Life Sciences IPO is expected to be finalized on December 16, 2024.
Kfin Technologies Limited is the registrar for the Sai Life Sciences IPO, managing allotment and refunds.
No significant governance issues or red flags have been reported regarding the leadership or board structure of Sai Life Sciences Ltd.
No Result Found
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading